A Sanofi spokesperson told ET that a glut of supplies added during Covid-19 and the struggle to win contracts from Unicef for its critical 5-in-1 pediatric vaccine Shan5 forced the company to assess its India operations.
from Industry-Economic Times
Read The Rest:economictimes...